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Abstract
Background: In this study, we sought to estimate the societal cost of illness in dementia in Sweden in 2012 using
different costing approaches to highlight methodological issues.
Methods: We conducted a prevalence-based cost-of-illness study with a societal perspective.
Results: The societal costs of dementia in Sweden in 2012 were SEK 62.9 billion (approximately €7.2 billion,
approximately US$9.0 billion) or SEK 398,000 per person with dementia (approximately €45,000, approximately
US$57,000). By far the most important cost item is the cost of institutional care: about 60% of the costs. In the
sensitivity analysis, different quantification and costing approaches for informal care resulted in a great variation
in the total societal cost, ranging from SEK 60 billion (€6.8 billion, US$8.6 billion) to SEK 124 billion (€14.1 billion,
US$17.8 billion).
Conclusions: The societal costs of dementia are very high. The cost per person with dementia has decreased
somewhat, mainly because of de-institutionalisation. The majority of the costs occur in the social care sector, but
the costing of informal care is crucial for the cost estimates.
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Background
Dementia disorders are chronic, long-lasting diseases
that impair cognition, social capacity and daily functioning
of the persons affected. As a consequence, dementia
heavily influences the situation not only for the patients
themselves but also for family members and other next of
kin. Furthermore, dementia disorders are also very
resource-demanding and costly, which, in a setting of
scarce public resources and, in many countries, ongoing
changes in care systems, puts great stress on decision
makers and budget holders. The worldwide societal cost
of dementia care was estimated to be US$604 billion for
36 million persons with dementia (PWD) in 2010 [1, 2].
The magnitude and allocation of resource use and costs
are of interest when present and future care is discussed
in terms of organisation, volume and financing.
The situation in dementia care is dynamic. Demo-
graphic prognoses predict a rapid increase in the number
of people affected [3–5], making the situation even more
urgent, and apocalyptic scenarios of the ‘dementia bomb’
and suchlike have been presented [6]. In contrast, some
studies have indicated that age-specific incidence and/or
prevalence of dementia and cognitive impairment might
have decreased in high-income countries such as the
United States, the United Kingdom, The Netherlands
and Sweden [7–11]. Symptomatic drug treatment for
Alzheimer’s disease has been available for almost
20 years. Studies on potential disease-modifying agents
have so far not been successful, although there are still
many compounds in clinical development [12, 13].
Because of changes in long-term care policies, as well
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as strategies and pressures for cost containment in
health care and social care systems, there is a trend
towards de-institutionalisation in some countries [14].
In 1991, the cost of illness (COI) in Sweden was
estimated to be 31 billion Swedish krona (SEK) for a de-
mentia population of 154,000 (which is probably an
overestimate of the prevalence) [15]. For 2000, the cost
was estimated to be SEK 38 billion for 133,000 PWD
[16], and for 2005, it was estimated as SEK 50 billion for
142,000 PWD [17]. There is also a wide range in esti-
mates of COI for dementia in other countries [18]. Of
course, there are true differences in the COI of demen-
tia, but the variability in COI figures could also be the
result of methodological issues, such as prevalence
sources, whether costs of informal care are included and
how care is quantified and costed or whether clinical/
convenience samples or population-based studies are
used as sources for the cost estimates.
The purpose of this paper was to estimate the societal
COI of dementia in Sweden in 2012, using different ap-
proaches to highlight methodological issues. We also
aimed to compare the time trend in COI from 2000 to
2012 when using similar methods. This paper is based
on a report that was commissioned by the Swedish
National Board of Health and Welfare (NBHW) [19].
Methods
COI approach
COI studies can be prevalence- or incidence-based [20].
If the aim is to estimate the economic burden during a
certain time period, the prevalence approach is recom-
mended; however, if the aim is to illustrate the economic
consequences of policy change (e.g., prevention, treat-
ment, changes in care organisation), the incidence ap-
proach may be preferred [21]. Another issue is whether
a bottom-up or top-down approach is to be used (or a
combination of the two). In a bottom-up study, resource
use and costs of a defined (often local) population are
described in detail, and, in a step 2, results are extrapo-
lated to a much larger population, such as all persons
with the disease in a country. Such results can be based
on cross-sectional point estimates or on longitudinal
data. Study populations in bottom-up studies can be
population-based or be derived from other kinds of
study populations (e.g., clinic/hospital-based, convenience
samples). In top-down studies, the share of total resource
use and cost of care in the region that is attributable to
the disease of interest are calculated, often using data from
registers and other databases. A combination of the two
approaches may also be required, depending on data avail-
ability. The distinction between costs for patients with a
certain disease (‘gross costs’) and costs due to the disease
(‘net costs’) is important; attributability of costs to a spe-
cific condition cannot be observed directly, but can only
be inferred (e.g., by comparing with costs for subjects
without the condition).
The perspective of a COI study defines the viewpoint
of the calculations. The societal perspective includes all
costs, regardless of the payer, and is recommended by
most published guidelines for economic evaluations [22].
In the case of dementia, this means that informal care is
assigned a cost. The viewpoint can also be narrowed
down, such as a county council, a municipality, an insur-
ance company or a health maintenance organisation.
Costs are often divided into direct costs (‘costs of re-
sources used’ for medical and social/non-medical care)
and indirect costs (‘costs of resources lost’ due to pro-
duction losses because of morbidity and mortality).
Informal care by non-professionals such as next of kin
may be difficult to classify in these terms. If the informal
carers are being remunerated to some extent, it may be
regarded as a direct cost, though this often applies to
only a low proportion of the total caregiving time. If the
carer has partly given up work to care for the PWD, this
constitutes an indirect cost equal to the value of the lost
productivity. Informal care by retired persons or care
during ‘non-working’ time is more complicated to evalu-
ate and assign an opportunity cost, because there is no
market for this resource.
In this paper, we apply several methodological ap-
proaches. We use a prevalence-based societal perspective
in which both bottom-up and top-down methods are
employed, and we also present estimates of both gross
and net costs.
Epidemiology
In a prevalence-based COI study, the number of persons
with the disease in question is essential. Because individual
diagnoses of all PWD are not available, estimates of the
number of PWD are necessary. Such estimates are based
on demographic statistics (from Statistics Sweden in
this paper) and age-specific dementia prevalence figures
(e.g., in 5-year classes). In this paper, we use such meta-
analysis-based figures presented by the Swedish Agency
for Health Technology Assessment (SBU) [23]: 1% for
persons aged 60–64 years, 1.5% for 65–69 years, 3% for
70–74 years, 6% for 75–79 years, 13% for 80–84 years,
24% for 85–89 years, 34% for 90–94 years and 45% for
95 years and older. Because there is a discussion cur-
rently regarding age-specific dementia prevalence [10],
we also present results based on other prevalence
sources [3, 8, 9, 24–28] in the sensitivity analysis. In the
base option, we assume that in 2012 there were 158,000
PWD in Sweden. The number of incident cases of de-
mentia in Sweden in 2012 (based on demographic sta-
tistics and adjusted for prevalent dementia cases) and
the meta-analysis by Fratiglioni et al. [29] is estimated
at 25,000 persons.
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Care organisation in Sweden
PWD in Sweden receive care using several care alterna-
tives. Basically, health care is provided by doctors, regis-
tered and enrolled nurses, occupational therapists and
physiotherapists, in the own homes of the elderly, in an
institution or in hospitals. The municipality’s social ser-
vices offer home help, such as help with daily activities
(shopping, cooking, cleaning and laundry and/or per-
sonal care such as help with feeding, bathing, toileting,
getting [un]dressed and into/out of bed). There is also a
range of other services, such as home nursing, transpor-
tation services, day care, short-term institutional care,
meals on wheels, security alarms, housing adaptations
and technical aids. A varying amount of informal care is
also common at home. (There is also a small amount of
informal care in institutions [30].)
Medical direct costs include costs of hospital care,
physician clinic visits, physician visits in primary care,
visits to emergency units without hospitalisation, visits
to and by rehabilitation staff, drug costs and costs of
diagnoses. Non-medical direct costs include costs of in-
stitutional care, day care and social services. In this
paper, indirect costs are restricted to production losses
for patients.
To distribute the Swedish population of PWD (158,000
persons) in the care system for the elderly in 2012, we use
a combination of results from bottom-up figures, mainly
from population-based projects such as the Kungsholmen
project [30, 31] and the Swedish National Study on Aging
and Care (SNAC) [32, 33], as well as national top-down
data [34–38]. Institutional care is divided into three types:
nursing homes, group living for PWD and ‘other’ types of
sheltered housing (e.g., different types of residential care
facilities) [16]. On the basis of population-based studies,
58% of PWD were assumed to live at home and 42% in
different kinds of institutional care at various proportions
(40–100%) (Table 1).
Resource use and costs
The list of potential resources that PWD might use is
large, and it is necessary to focus on resource items that
are significant cost drivers. All costs are expressed as
2012 SEK (1 € = SEK 8.77, 1 US$ = SEK 6.96).
Direct costs
Social care sector Care for PWD in the social care
sector consists of support at home by home help, day
care, respite care and long-term institutional care.
Home care About 92,000 PWD are estimated to be
living at home. For the quantification of support at
home, we used the approach of the Resource Utilization
in Dementia (RUD) instrument [39], where formal (and
informal) care is divided into three proportions: support
in personal/basic activities of daily living (PADL), instru-
mental activities of daily living (IADL) and supervision.
For home help services, we used figures based on PADL
and IADL. On the basis of Swedish studies where the
RUD instrument has been used [40, 41], we estimated
the average daily support at 0.5 h/day. This average fig-
ure also includes zero users. The hourly cost for formal
home care is derived from the Swedish Association of
Local Authorities and Regions (SALAR) [42].
Day care The Swedish Dementia Registry (SveDem) was
established in 2007. It is an Internet-based quality regis-
ter where several indicators can be followed over time
according to national guidelines, such as diagnostic
workup, medical treatment and support from commu-
nity [43]. On the basis of extrapolations from the annual
reports from SveDem [44] (adjusted for incomplete
coverage), we estimate that 10,000 PWD have access to
day care every year. The annual unit cost for day care is
derived from statistics from the NBHW [45].
Institutional care The method of classifying institu-
tional care in Sweden has changed over the years. In a
report for the NBHW regarding staffing of long-term in-
stitutional care, three levels were used: living in facilities
purposely designed for people with dementia (group
living, collective living, group dwelling) [36], high-
staffed (e.g., nursing homes) and low-staffed (residential
care facilities). Table 1 displays the distribution and
proportions of PWD in the different forms of institu-
tional care, based on updates of the previous COI esti-
mates [16, 17] and calculations in the Swedish national
dementia guidelines [46]. There are also small numbers
of PWD younger than 65 years of age as well as PWD
using short-term respite care embedded in institutional
facilities (annualised rate).
Dementia nurse An expanding and valuable resource in
dementia care is the dementia nurse, who organises
Table 1 Estimated distribution of the Swedish population with




At home 58 91,900
Of those with respite care 3900
Institution 42 66,100
All institutional care
Higher staffed 75 19,000
Group living 100 30,000
Lower staffed 40 14,000
Institutionalised <65 years old 3100
All 158,000
PWD Persons with dementia
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support for families, coordinates care and also works
with overall planning of dementia care. It is estimated
that there were about 500 such nurses in 2012 [47]. As
unit cost for the dementia nurses, we used the average
monthly salary for specially trained nurses, including the
social security charges [48].
Medical care sector costs Care for PWD in the medical
care sector consists of hospital care, visits to primary
care, visits to various specialist clinics (including some
of the costs for diagnostic procedures), visits to emergency
rooms, use of rehabilitation resources and drug use. The
unit costs for these resources are derived mainly from the
costing database from SALAR [49].
Hospital care Figures regarding the use of hospital
inpatient care are derived from the Swedish National
Patient Register for the diagnoses F000, F001, F002,
F009, F012, F020, F021, F022, F023, F028, G300, G301,
G308 and G309 [50].
Outpatient care visits Similarly to the figures for in-
patient hospital care, visits to specialists were derived
from the National Patient Register [50]. Regarding other
outpatient care visits (e.g., primary care, occupational
therapists, physiotherapists), there is no national statis-
tical source available. However, on the basis of data from
the SNAC project [51–53], it was estimated that PWD
made two visits per year to family physicians and four
visits each per year to district nurses, occupational
therapists and physiotherapists.
Diagnosis On the basis of an inquiry by the Swedish
Ministry of Health to specialist clinics, it was estimated
that there were 14,000 diagnostic workups per year in
2003 [34]. In the SveDem register, about 4000 newly di-
agnosed PWD are registered every year [44]. According
to a recent questionnaire sent from SveDem to the
memory clinics in Sweden, about 50% of those who went
through the diagnostic workup got a final dementia
diagnosis. Because the register does not have a com-
pletely nationwide coverage, we assume that there still
are 14,000 diagnostic workups in specialist care. The
figures for primary health care are more difficult to esti-
mate. In SveDem, about 3500 newly diagnosed PWD are
registered in primary care. About two-thirds of the pri-
mary care centres are part of SveDem, and, given the
assumption that 50% also get a dementia diagnosis in
primary care, we assume that there are about 10,000
diagnostic procedures in primary care every year. In a
paper from SveDem, the costs for diagnostic workup
were estimated to be SEK 7017 in primary care and SEK
12,095 on the specialist level. These cost figures are in
line with those reported in another Swedish paper from
the Kalmar region of Sweden [54].
Drug use The Nordanstig and Kungsholmen SNAC sites
in Stockholm include individual and diagnosis-related
(e.g., dementia) information about drug use and its re-
lated costs [55].
Informal care Quantification and costing of informal
care and unpaid work are controversial and complicated
issues [56–58]. It is challenging to delimit time spent by
caregivers on different caregiving tasks (e.g., supervision)
and to determine whether each activity has an opportun-
ity cost (i.e., what is the value of the caregiver’s time in
its best alternative use). We relied on several previous
studies in which researchers used the RUD framework
to estimate caregiving time [39]. To avoid overestimates
of informal care, we aimed to use population-based data
wherever possible. One such source is the Nordanstig
project [40], and now we can also add data regarding the
amount of informal care from the database in the SNAC
project (baseline 2001–2003 and follow-up 2007–2009).
On the basis of information from these sources, we esti-
mate that PWD receive a daily support of 1.9 h in PADL
and IADL. We also have data from other Swedish studies
on informal care with the RUD instrument [41, 59, 60]. In
these studies, the range was 1.5–3.3 h per day in PADL
and IADL support. These figures, as well as data on super-
vision needs, are used in the sensitivity analysis.
Several costing approaches have been discussed [56, 61–64].
In theory, informal care should be valued by the oppor-
tunity cost of the carers’ time. However, identifying this
opportunity cost is not straightforward [65]. Market prices
are not available, except for carers of working age, and, in
many cases, it is not apparent what the ‘best alternative
use’ of the carers’ time is. The main providers of informal
care are spouses and the children/children’s spouses of the
PWD. Thus, in the base case, the cost of informal care is
weighted and based on studies where the proportion of
spouses (two-thirds) and children (one-third) as carers is
estimated [33, 40, 66]. For the daughters/daughters in law
and sons/sons in law, the average cost per hour of paid
work (SEK 270) was used [67], whereas for leisure time,
we used the opportunity cost per hour as 35% of the aver-
age wage [68]. The resulting weighted hourly cost of infor-
mal care was SEK 152. In the sensitivity analysis, other
costing approaches are presented.
Indirect costs
Most people with dementia are retired, but those youn-
ger than age 65 years are of working age. On the basis of
register data from the Swedish Social Insurance Agency,
431 persons were prematurely retired or on sick leave
due to dementia diagnoses. This is probably a low
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estimate because PWD often are on sick leave for other
diagnoses. The figure is also based on the main diagnosis
in the register. Furthermore, early retirement or sick
leave by other family members is not incorporated into
these figures. The unit cost is based on the average wage
for the people aged 55–65 years [67] and not on the
transfer costs for the retirement or sick leave. The unit
costs are summarised in Table 2. Most of the cost sources
were derived from official authorities and registers.
Sensitivity analysis
Owing to the variability in underlying sources and different
quantification and costing approaches, several other pa-
rameters were tested in a sensitivity analysis. There are
many other sources for age class prevalence, and in recent
years several studies indicating a decline in prevalence have
been presented, although some other estimates suggests an
increase (European Brain Council [24], Matthews et al. [8],
Lobo et al. [25], SNAC-Kungsholmen [9], EURODEM
[26], Alzheimer Cooperative Valuation in Europe [27],
EuroCoDe [28] and Alzheimer’s Disease International
[ADI] [3]). Owing to the discussions regarding the
quantification and costing of informal care, several al-
ternative options have been tested: the amount of infor-
mal care with supervision added to activities of daily
living (in total 4.7 h/day), alternative sources for the
amount of informal care (1.5–5.3 h/day in PADL and
IADL) [41, 59, 60, 69], various costing of informal care
(a zero value, a replacement cost instead of opportunity
cost, SEK 434/h [42] and an alternative source for the
opportunity cost [SEK 31/h, based on the Swedish Road
Association] [70]). Institutional care costs are one of
the heaviest cost drivers in dementia care. Figures re-
garding the proportion of PWD in different forms of
institutional care also vary [30, 32, 33, 51–53, 71], and
thus we test an option where the proportion of PWD is
lower. The unit costs for institutional care are also
varied (25th and 75th percentiles).
Cost attributable to dementia (‘net’ costs)
The costs presented as the main option can be regarded
as ‘gross costs’ because they comprise the costs of PWD
including costs for conditions other than dementia. One
way to estimate costs that are attributable to dementia
(‘net costs’) is to calculate the cost difference between
costs for PWD and for people without dementia. The es-
timates are based on the total direct costs of care for the
elderly in Sweden (65 years old and above), which in
2012 were SEK 182 billion, covering 102 billion SEK in
the social care sector (municipalities) and SEK 80 billion
in the health care sector (the county councils) [38]. Esti-
mates are possible for the population 65 years and older,
which represented about 148,000 of the 158,000 PWD in
2012. It is assumed that the costs for PWD aged 65 years
and older are the same as those for all PWD. The in-
fluence of production losses on PWD was so low that
this was not included in the ‘net’ cost estimates. The
net costs can be estimated using a step-by-step procedure
(see Table 7 in the Results section below).
Results
The total societal costs of dementia in Sweden in 2012
were in the base case estimated at about SEK 63 billion
(Table 3). By far the most important cost driver is the
cost of long-term institutional care (SEK 38 billion). Fur-
thermore, almost 80% of the total costs occur in the mu-
nicipalities’ social care sector. The cost of informal care
constitutes 17%, whilst the medical care sector within
the county council represents only a small proportion
(5%). The costs of drug use constitute almost 39% of the
health care sector costs.
When comparing with the previous COI studies [16, 17],
some adjustments are needed because the 2012 figures
comprise more cost items. The total costs are rather simi-
lar in 2000, 2005 and 2012 (Table 4), but while the number
of PWD has increased, the cost per PWD has decreased.
The main reason for the reduced cost per PWD is that the
proportion of PWD who are estimated to be living in insti-
tutions has decreased from about 56% in 2000 to 42% in
2012; during that period, the number of institutional beds
in Sweden was reduced from about 120,000 in 2000 to
95,000 in 2012.
Table 2 Unit costs in base case
Unit cost (SEK)a Reference
Medical care sector
Hospital care 4780/day [49]
Emergency room visits 2988/visit [49]
Outpatient care visits (specialists) 3918/visit [49]
Primary care physician visits 1140/visit [83]
Other outpatient care visits 931/visit [49]
Drug use 7080/year [55]
Diagnosis in primary care 7017/diagnosis [84]
Diagnosis in specialist care 12,095/diagnosis [84]
Social care sector
Higher-staffed institutional care 606,134/year [42]
Group living 606,134/year [42]
Lower-staffed institutional care 472,828/year [42]
Day care 98,900/year [45]
Home services 434/h [42]
Dementia nurse 56,250/year [48]
Informal care 152/h [67, 68]
Indirect costs 357,600/year [67]
a1 € corresponds to SEK 8.77 and 1 US$ to SEK 6.96
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The most striking finding in the sensitivity analysis is
the great range in costs with different approaches of
costing informal care (range SEK 7.6 billion–71.5 billion)
with a corresponding great variation in total societal
cost, ranging from SEK 52 billion to SEK 124 billion
(Table 5).
In the other options in the sensitivity analysis (Table 6),
the differences vs the base case were smaller. The rather
low variation of costs with different prevalence sources
is due to an assumed similar proportion of PWD in
institutions.
The direct cost that we assumed was related to de-
mentia solely (‘net costs’) was about SEK 40 billion
(Table 7), which constitutes about 76% of the ‘gross’
direct costs (and about 80% of total societal costs if it is
assumed that all informal care is related to dementia).
Discussion
Three major findings are obvious: (1) The costs of de-
mentia care are very extensive; (2) the majority of the
costs occur in the social care sector (the municipalities);
and (3) the quantification and costing of informal care are
crucial for the cost estimates. When the Swedish figures
(total costs of SEK 400,000 [approximately € 45,000, ap-
proximately US$ 57,000]) are compared with other COI
figures, the need for transparency is clear. In a review,
Jönsson and Wimo found a range between €6000 and
€64,000 per case in different European countries, where
the main reason for this variation was methodological is-
sues [72]. A similar variation in worldwide COI studies
was found in the dementia report by the SBU [23]. In the
worldwide cost estimates presented by ADI [1], it was
concluded that, besides methodological issues, the inter-
action between informal care and the social care sector
(including, e.g. long-term institutional care) was crucial
for the cost differences: low/no resources for long-term
institutional care resulted in a high proportion of the costs
of informal care and vice versa.
The most important cost driver in Sweden is the cost
of institutional care. The institutional concept is wide
and includes a variety of care settings where the least
common denominator, in our opinion, is staffing
around the clock. We have used three institutional
levels (nursing homes, dementia-designated care such
as group living [73] and residential care alternatives for
the aged or similar) to cover the different content of
care and costs, and in the sensitivity analysis we have a
further variation in costs of institutional care. Although
some range occurs in the costs of institutional care in the
sensitivity analysis, it is not of the same magnitude as
when different approaches for the quantification and cost-
ing of informal care were tested [61]. In the literature,
there is an extensive variation in the quantity, ranging
from 1.5 h to 16 h per day [61, 72, 74–76]. This great
Table 3 Total societal costs of dementia in Sweden in 2012
(base option)
Cost (million SEK)a Per PWD, SEKa Proportion
Medical care sector
(county councils)













Drug use 1120 1.8%












Day care 989 1.6%
Home services 7372 11.7%
Dementia nurses 338 0.5%
Total social care sector 49,262 311,783 78.3%
Indirect costs 118 744 0.2%
Totalb 62,920 398,226 100.0%
PWD Persons with dementia, SEK Swedish krona
a1 € corresponds to SEK 8.77 and 1 US$ to SEK 6.96.
bDiscrepancies are due to rounding
Table 4 Societal cost of dementia (in millions SEK, adjusted to
cost level of 2012) in 2012, 2005 and 2000 in different sectors
2012 2005 2000
Costa % Costa % Cost %
Medical
care sector
2848 5.0% 2701 5.0% 3277 5.9%
Social
care sector
44,681 78.1% 43,275 79.4% 45,542 82.5%
Informal care 9534 16.7% 8065 14.8% 6017 10.9%
Indirect costs 118 0.2% 447 0.8% 358 0.6%







PWD Persons with dementia, SEK Swedish krona
a1 € corresponds to SEK 8.77 and 1 US$ to SEK 6.96. Cost items are adjusted
to be similar; thus, costs are not identical to Table 3 for 2012
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variation depends mainly on how many components of
informal care are included; the lower figures represent
only PADL support, while the higher figures also in-
clude IADLs and supervision/surveillance. Another
factor is whether the sources of informal care are based
on clinical/convenience samples or on population-based
studies, the latter including zero values with lower hourly
figures as a result. The costing issue is also crucial, and
several methods have been proposed [56, 61–64]. The
assumptions used for the mix between informal carers of
working age and retired carers also have implications for
the costing approach as well as for long-term care policies
[77]. Although the opportunity cost is recommended by
most economists, it is not always easy to identify it [65].
Market prices are not available, except for carers of
working age, and, in many cases, it is not apparent what
the ‘best alternative use’ of the carers’ time is. Thus re-
placement costs or average wage or suchlike are used in
many COI studies, most often resulting in higher costs.
Because the different methods of quantification and
costing of informal care resulted in such a great difference
in final costs, it is obvious that this issue needs transpar-
ency but must also be a target for future methodological
discussions. Validated instruments are essential where it is
clear how informal care is quantified as well as a trans-
parent presentation of how unit costs for informal care
Table 5 One-way sensitivity analysis of costs of informal care
Hours/day Hourly cost Total costa (billion SEK) Informal carea (billion SEK) Cost per PWDa (SEK)
Base case 1.9 152 62.9 10.6 398,000
Higher amount of hours 3.3 152 70.2 18.0 445,000
Supervision time added 4.7 152 77.4 25.4 490,000
Replacement cost 1.9 434 82.6 30.3 523,000
Supervision time added and replacement cost 4.7 434 123.8 71.5 784,000
Alternative opportunity cost 1.9 109 59.9 7.6 379,000
Zero cost for informal care 0 0 52.3 0 331,000
PWD Persons with dementia, SEK Swedish krona
a1 € corresponds to SEK 8.77 and 1 US$ to SEK 6.96
Table 6 Other one-way sensitivity analyses
Varied entity Value Costa (billion SEK) Cost per PWD Source [reference]
Prevalence (number of PWD) 158,000 62.9 398,000 Base case
Prevalence 113,000 54.1 478,000 EBC [24]
Prevalence 117,000 54.8 469,000 Matthews et al. [8]
Prevalence 123,000 56.0 455,000 Lobo et al. [25]
Prevalence 128,000 56.6 453,000 SNAC-K [9]
Prevalence 148,000 60.9 412,000 EURODEM [26]
Prevalence 151,000 61.5 408,000 ALCOVE [27]
Prevalence 168,000 64.9 386,000 EuroCoDe [28]
Prevalence 169,000 65.1 385,000 ADI [3]
Home care: per executed hour 558 63.8 404,000
Home care: median hourly cost 420 61.6 390,000 [42]
Home care: 25th percentile per hour 378 60.9 385,000 [42]
Home care: 75th percentile per hour 473 62.5 395,000 [42]
Institutional care: 25th percentile
(low staffed and high staffed)
363,920 and 565,811 59.1 374,000 [42]
Institutional care: 75th percentile
(low staffed and high staffed)
534,142 and 639,828 65.6 416,000
Institutional care: proportion PWD 50% in low-staffed, 80% in high-staffed 64.2 406,000
Institutional care: proportion PWD 40% in low-staffed, 50% in high-staffed 59.1 374,000
PWD Persons with dementia, SEK Swedish krona
a1 € corresponds to SEK 8.77 and 1 US$ to SEK 6.96
EBC European Brain Council
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are obtained and valued. A sensitivity analysis is crucial
to highlight the variability and to make comparisons
with other studies possible.
The relatively high proportion (39%) of drug costs in
the total costs of the county councils may have several
explanations. First, the county councils pay for all drug
use of PWD, even if, for example, they are cared for in
municipal nursing homes. Second, the costs of hospital
care as well as the costs of outpatient specialist care are
based on register data, where a diagnosis of dementia
often is not registered even if a patient has a dementia
disorder [78]. Thus, these costs may be underestimated,
resulting in a relatively higher proportion of the costs of
drugs for the county councils. In contrast, even if
there is a debate regarding the prevalence of dementia
[7–11], the use of different prevalence sources in the
sensitivity analysis did not alter the COI figures
significantly.
Although the societal costs of dementia are substantial,
the costs per person were lower in 2012 than in 2000 and
2005. The main reason is the de-institutionalisation trend
in Sweden. The number of long-term care beds in institu-
tions in Sweden (persons aged 65 years and above)
decreased from about 119,000 in 2000 to 100,400 in 2005
and 90,500 in 2012 [79], which resulted in lower costs
(per person) in 2012 than in 2000 and 2005. Conse-
quently, the relative impact of costs of informal care has
increased. This reflects, at the same time, a gradual shift
of responsibilities from the state to the families. The ques-
tion whether this is good or bad cannot be answered by a
COI study. There are no assessments of the quality of care
or the quality of life of PWD or the informal carers in
our data. Such consequences can be analysed with ins-
truments such as DEMQOL (for PWD) [80] or CarerQol
(for informal carers) [81], and they are usually incorpo-
rated as outcomes in cost-effectiveness analysis of inter-
ventions. In light of expected demographic changes,
with a considerably rapid increase in the numbers of
people aged 80 years and older after 2020 [82], these
trends in the change of the care structure need a pro-
found analysis.
It is obvious that transparency is crucial in COI studies,
otherwise comparisons are not meaningful. A comprehen-
sive and transparent sensitivity analysis also highlights
different analytical approaches, which makes compari-
sons with other COI studies easier.
Table 7 Estimated ‘net’ costs of dementia (SEK)
Social care sector Medical care sector Total
Step 1
Direct cost of care for people aged 65+ years 101,756 79,973 181,729 million SEK
Direct costs of dementia 49,262 2904 52,166 million SEK
Direct costs for PWD aged 65+ yearsa 46,144 2720 48,864 million SEK
Direct costs of care for people without dementia
aged 65+ years
132,865 million SEK
Number of people aged 65+ years 1,828,283
Number of people aged 65+ years without dementia 1,680,283
Direct cost per person aged 65+ years without dementia 79,073 SEK
Step 2: costs per PWD
Gross cost per person with dementiaa (Table 2)b 398,226 SEK
Exclude: direct cost for person without dementia as above 79,073 SEK
Exclude: costs of informal care of PWD (Table 2) 67,318 SEK
‘Net’ direct costs 251,836 SEK
‘Net’ total costs (including informal care) 319,154 SEK
Step 3: aggregated costs
Aggregated ‘net’ direct costs of dementia aged
65+ years (148,000 PWD)
37,272 million SEK
Aggregated ‘net’ direct costs all dementia (158,000 PWD) 39,790 million SEK
Aggregated ‘net’ costs all including informal care aged
65+ years (148,000 PWD)
47,235 million SEK
Aggregated ‘net’ costs all including informal care all
dementia (158,000 PWD)
50,426 million SEK
PWD Persons with dementia, SEK Swedish krona
aAssumptions: similar for PWD aged 65+ years as for all PWD and adjustment factor (here, dementia aged 65+ years only) 148,000/158,000
b1 € corresponds to SEK 8.77 and 1 US$ to SEK 6.96
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Conclusions
The societal costs of dementia are very high. The cost
per PWD has decreased somewhat, mainly because of
de-institutionalisation. The majority of the costs occur
in the social care sector, but the costing of informal care
is crucial for the cost estimates.
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